Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.61 and a 12-month high of $16.27. The firm has a market capitalization of $128.99 million, a P/E ratio of -0.73 and a beta of 1.75.
Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27. The stock has a market cap of $128.99 million, a P/E ratio of -0.73 and a beta of 1.75.
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...
In a report released on March 26, Michael Schmidt from Guggenheim maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $6.00. The company’s ...
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $10.00. The company’s shares ...
Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer ...
Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin ...
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...
Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian ...
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback